Rui Du

Rui Du

Auto-generated profile, based on publicly available information

Rui Du

School of Basic Medical Science, Tsinghua Medicine, Tsinghua University , Beijing

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 June 2026 in Nephrology Dialysis Transplantation
Verified
Journal Article
Closed access
RDRui Du
Rui Du
HWHannah Wallace
Hannah Wallace
JHJeffrey T Ha
Jeffrey T Ha
BTBen Talbot
Ben Talbot
VPVlado Perkovic
Vlado Perkovic
SKSradha Kotwal
Sradha Kotwal
Background and hypothesis: Chronic kidney disease (CKD) is a growing global health burden. While studies have demonstrated sex disparities in CKD prevalence and outcomes, evidence on sex-based differences in therapeutic management remains limited. This analysis aims to assess sex disparities in the receipt of evidence-based medications in a global CKD cohort. Methods: This study is a substudy of the Global Kidney Patient Trials Network, a prospective, observational, international cohort of CKD patients. The exposure of this study is biological sex, and the main outcomes are the receipt of evidence-based medications for CKD, including renin–angiotensin system inhibitors (RASis), sodium–glucose co-transporter 2 inhibitor (SGLT2i), and diuretics. Adjusted multivariable logistic models were conducted to examine associations between sex and proportion of receiving medications, as well as the interactions between sex and other key clinical characteristics (advanced age, high Kidney Disease: Improving Global Outcomes prognosis risk, and comorbid condition). Results: A total of 4192 participants were eligible, and 40.9% were female. Females had lower odds of receiving RASi [odds ratio (OR) = 0.75, 95% confidence interval (CI) 0.64–0.88; P < .001] and SGLT2i (OR = 0.79, 95% CI 0.64–0.98; P = .03) compared to males, after adjusting for age, region, systolic blood pressure, body mass index, presence of cardiovascular disease and diabetes, CKD aetiology, and prognosis risk, with no significant difference in the receipt of diuretics. There were no significant interactions between sex and any other key clinical characteristics, indicating that the disparities in the receipt of RASi and SGLT2i remained consistent across high-risk subgroups. Conclusion: Female patients with CKD are less likely to receive evidence-based medications than males, irrespective of established CKD risk factors. This difference highlights potential inequities in treatment globally that may result in outcome disparities.

2 June 2026 in Kidney360
Verified
Journal Article
Open access
NSNasir A. Shah
Nasir A. Shah
RDRui Du
Rui Du
BNBrendon L. Neuen
Brendon L. Neuen
ALAdeera Levin
Adeera Levin
VJVivek Jha
Vivek Jha
SKSradha S. Kotwal
Sradha S. Kotwal
Key Points: Both patients and clinicians were broadly supportive of combination therapy in CKD. Implementation remains the main challenge, especially how to start and sequence drugs. Background: CKD affects approximately 15% of adults and remains a major cause of kidney failure and cardiovascular events. Several newer drug classes—sodium-glucose cotransporter 2 inhibitors, nonsteroidal mineralocorticoid receptor antagonists, glucagon-like peptide-1 receptor agonists, and endothelin receptor antagonists—provide additional kidney and cardiovascular protection added to standard-of-care renin-angiotensin system inhibition, but the real-world acceptability of using these agents in combination is uncertain. To evaluate the willingness of people with CKD and clinicians to use multidrug combination therapy and to characterize perceived benefits, risks, and barriers to implementation. Methods: We conducted a cross-sectional, descriptive, semiquantitative online survey of adults with CKD and clinicians who prescribe CKD therapies. Parallel questionnaires captured demographics, current treatment, prior experience with multidrug regimens, willingness to receive or prescribe combination therapy, and ranked priorities and concerns. Results: One hundred forty-two people living with CKD and 317 clinicians completed the survey. Most CKD respondents resided in Australia or the United Kingdom; most surveyed clinicians were hospital-based physicians. Willingness to use multiple agents to reduce CKD progression was high (113/142, 80% “yes”; 27/142, 19% “maybe”). Respondents with CKD prioritized reducing CKD progression and preventing complications, while highlighting side effects, long-term safety, and drug-drug interactions as key concerns; pill burden and cost were less frequently prioritized. Clinicians strongly supported combination therapy in a trial context (300/317, 95%) and reported basing prescribing on guideline recommendations, trial evidence, kidney function, and albuminuria. Principal barriers were risks of hyperkalemia and acute eGFR decline, intensified biochemical monitoring, and cost/limited access. Most clinicians preferred staggered rather than simultaneous initiation, typically starting with a sodium-glucose cotransporter 2 inhibitor as the first add-on to background renin-angiotensin system inhibitor therapy. Conclusions: People with CKD and clinicians support multidrug combination therapy, but concerns regarding safety, monitoring burden, and affordability must be addressed to enable routine implementation and large-scale trials.